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Abstract 
Osteoporosis is a progressive bone disease that over time, bone mass, and 
therefore bones strength, is decreased, due to depletion of calcium and bone 
protein. So, bones become fragile and break easily. The unique ability of human 
parathyroid hormone (hPTH) as a bone anabolic agent, to increase bone density 
makes it a promising anabolic agent in the treatment of osteoporosis. 
Parathyroid hormone secreted by parathyroid chief cells is composed of 84 
amino acids act as one of the major hormones maintaining calcium 
homeostasis. Anabolic agents directly stimulate bone formation and improve 
the microarchitecture of bone. Hence, they have the potential to increase bone 
mass by promoting the growth of new bone greater extent than antiresorptives 
that inhibit bone resorption. N-terminal fragment (amino acids 1–34) of human 
parathyroid hormone was regarded to cover most of the hormonal actions of 
the intact human parathyroid hormone named teriparatide and is currently the 
only FDA approved anabolic medication for osteoporosis. According to some 
reports, the C-terminal region of the full-length PTH (1–84) may play an 
important role in its biological function. The C-terminus of PTH can regulate 
calcium concentration released from bone through binding to a different PTH 
receptor specific for the C-terminus. The aim of this study was to express and 
produce the recombinant PTH protein (1-84) in E.coli. 
Keywords: E.coli, osteoporosis, rhPTH 
Introduction 
Osteoporosis is a bone silent disease characterized by reduced bone mineral 
density (BMD) and bone architecture alterations, due to depletion of calcium 
and bone protein, which makes your bones weak and enhances probability of  
fractures(Quattrocchi & Kourlas, 2004). The unique ability of human 
parathyroid hormone (hPTH) as a bone anabolic agent, to increase bone  
density revolutionizes treatment of osteoporosis(Neer et al., 2001). Human 
parathyroid hormone (hPTH) is an 84 amino acid peptide which is secreted by 
the parathyroid chief cells in response to low bloodstream calcium 
levels(Diarmuid S. O’Riordain, 1997). The original  translation product is a 115 
amino acid pre-pro-human parathyroid hormone , During secretion ,the pre-pro 
part is cleaved off  to generate mature hormone, hPTH of 84 amino acid 
(Rokkones et al., 1994).  hPTH is a major hormone which regulates the calcium 
and phosphate homeostasis  through a variety of actions on target cells in bone 
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and kidney and remodels bone(Chunxiao et al., 2007) (Qin, Raggatt, & Partridge, 
2004) 
Although the anabolic effects of PTH(1-84) has been known , Extracellular 
biological function of hPTH  lies in  the N-terminal of the hormone hPTH(1–34) , 
that covers most of the biological activity of the hole hormone  and was named 
teriparatide(Hodsman et al., 2003). it increases the mineral density of  bone and 
stimulates bone mass formation in postmenopausal women with 
osteoporosis(Poole & Reeve, 2005). continuous administration 
(hyperparathyroidism) results in a catabolic skeletal effects that leads to 
stimulate osteoclast activity , cause loss of bone , accelerate bone turnover and 
increase the incidence of  fractures, while intermittent exposure to low doses of 
an N-terminal fragment of PTH has anabolic skeletal effects that directly 
stimulates bone formation and  increases bone density in each remodeling cycle 
, Increases number of active osteoblasts  ,levels of it’s activity  and  trabecular 
connectivity(Wang et al., 2010)(Poole & Reeve, 2005) .  Hence, As a result of its 
unique mechanism of effects, parathyroid hormone (PTH), the only FDA 
approved anabolic medication for osteoporosis , has  the potential to increase 
bone accrual by promoting the growth of new bone greater extent than 
antiresorptives  agent like vitamin D , estrogens , bisphosphonates that inhibit 
bone resorption (Hodsman et al., 2003). 
 Various lines of evidence suggest that   the   C-terminal region of the intact PTH 
(1–84) can play an important role in its biological activity(D’Amour & Brossard, 
2005). The C-terminus of hPTH can balance calcium homeostasis that released 
from bone through binding to a different PTH receptor specific for the C-
terminus like receptors on osteoblasts(D’Amour & Brossard, 2005).  
As a result  of  the biological importance and multiple beneficial properties of 
the different parts of hPTH and necessity pharmaceutical use of this hormone in 
the treatment of  osteoporosis  and  bone  disorders, obviously require an 
efficient  and functional procedure for obtaining large amounts of  hPTH using 
genetic engineering methods  must be set up. Great efforts have been made to 
produce high levels of hormone using recombinant DNA technology by 
Escherichia coli, Pichia pastoris and Saccharomyces cerevisiae, mammalian cells. 
Escherichia coli was the most common and the first choice prokaryotic host 
used to synthesis of recombinant DNA (rDNA) pharmaceutical and protein 
expression , initial development in commercial activities and  etc . 
The ease of growth, easy handling, high concentration of product, the 
physiological, biochemical and genetically knowledge respect to other 
microorganisms are some of it’s advantages. but observation showed  that  
there is no Uncertainty that expression level of recombinant  gene be high , 
because of the instability of mRNA and protein due to digestion by intracellular 
proteases, in E.coli (Murby et al., 1991). To overcome these problems, 
considerable amount of effort has been used and expression hPTH by fusion 
protein in E. coli had been suggested(Rabbani et al., 1988).Fusion protein is an 
important strategy that has been successfully used for producing soluble 
proteins with high yielding  efficiency  in E.coli, as the dominant aim of 
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recombinant protein expression is often to reach a high degree of aggregation 
of soluble product in the bacterial cell(Morelle & Mayer, 1988). 
 
More solubility of the expressed protein is one of benefits of using Thioredoxin. 
In addition, it is possible to obtain high level of expression by using fusion 
partner and it can be purified using IMAC regarding His6 tag binding affinity to 
N terminal of the expression cassette(Fu, Tong, & Wei, 2005). 
In this study, we indicated an effective procedure for production of intact hPTH 
in E. coli using a soluble fusion protein method. We constructed a pET32a(+) 
expression plasmids containing a newly designed synthetic gene allowing  
synthesis of a  His6-thioredoxin-hPTH (1–84) fusion protein under the control of 
the T7 promoter in E. coli(Liu, 2007). 
 
Material & method 
Material 
DH5α and BL21 (DE3) (Novagen, USA), strain of Escherichia coli, were used as 
the hosts for subcloning and gene expression, respectively. The plasmid pUC57, 
containing a 298 bp, His6-thioredoxin-hPTH (1–84) in MscI/BamHI cDNA 
fragment, was provided from GenScript (USA). The pET32a (+) expression vector 
was obtained from Novagen, USA. Restriction enzymes and T4 DNA ligase were 
purchased from New England Biolabs (UK). Cells were cultured in TB and LB 
medium(Sambrook J, 2001). 
 
Construction of expression vector  
The pUC57-PTH84 transformed into DH5α for amplification target gene. After 
subcloning, pUC57-PTH84 extracted by QIAGEN plasmid extract kits. The optical 
density of plasmid solution measured. For digesting His6-thioredoxin-hPTH     
(1–84) cDNA fragment from pUC57 ,18 µl plasmid solution (30 ng/µl), 1 µl 
BamHΙ (20,000 unit/ml) and 1.5 µl MscΙ (5,000 unit/ml) mixed and put in 
benmary at 37oC for 2h by 25 µl total volume.(Fig 1)  20 µl of pET32a (+) vector 
(50.4 ng/µl) was digested by same condition. Both of them loaded in 1% agaros 
gel. His6-thioredoxin-hPTH (1–84) cDNA fragment and digested pET32a (+), 
extracted by QIAGEN gel extract kits. Ligation in 10 µl total volume with 2.5 µl 
His6-thioredoxin-hPTH (1–84) cDNA, 2.5 µl digested pET32a (+) and 5 µl master 
mix ligase was done .The product of ligation was used for transformation into 
BL21 (DE3) competent cells.so we transformed pET32a (+)-PTH84 vector, in to 
BL21 (DE3).Appearing single colonies in LB agar medium containing Ampicillin 
(100 µg/ml) during overnight, confirmed transformation cells containing pET32a 
(+)-PTH84 vector. Colony-PCR verified accuracy of transformation expression 
vector into expression host. (Fig 2) 
Fermentation 
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Fermentation was carried out in a BioFlo 110 bioreactor (New Brunswick). 
Temperatures were monitored and kept on 37oc ± 0.1.  The  pH  was  measured  
by  a  glass  electrode  (Ingold)  and  maintained  at  6.8  through  addition  of  
either  1 mol/l H3PO4 or  NaOH.  Filter sterilized air and oxygen was supplied to 
the medium.  The  impeller  speed  was  regulated  to  keep  the dO2 (oxygen  
partial  pressure)  at  43%  air  saturation in  the  medium  .foam was removed 
by silicon anti-foam.  
Fusion protein expression in bioreactor 
100 µl of 2o% glycerol stock that preserved as fermentation seeds, cultured in 
LB agar medium overnight. Eight colonies were grown in 5 ml LB medium 
containing 100 µg/ml ampicillin. Best colony was selected by OD & 
densitometry. Best single colony was grown in 8 ml LB medium containing 100 
µg/ml ampicillin. Subculture for scaling up was done in 50 ml and 500 ml, 
respectively. 3 liter of TB medium inoculated with 500ml seed was cultivated at 
37oc, pH 7.0.  Feeding 1 (table 1) was initiated when OD595 of the culture 
reached 20. Protein expression was induced when OD595 of the culture reached 
100 by feeding 2 (table 1) and IPTG to a final concentration of 0.5 mM.  After 4h 
induction, cells were harvested by centrifugation (10000 rpm, 4oc, 30 min).         
(Fig3). 
Lysis of the cell 
Harvested cells were resuspended in DTT (Dithiothreitol) buffer and passed 
thrice through a homogenizer at 1200 bar. Then suspension was centrifuged 
(10000 rpm,4oc, 30min) to remove cellular debris. Supernatant was used for 
analyzing the amount of fusion protein with Glycine-SDS-PAGE. Protein 
concentration was measured according to method of Bradford With bovine 
serum albumin as standard (BSA). 
Analysis by SDS-PAGE   
Each sample diluted by appropriate sample buffer. All of them remained 5 min 
in boiling water and then 5 min on ice.2o µl of each one slowly loaded on wells 
for 45min and 250 V. (Fig 4) 
Result  
We ﬁrst transformed BL-21(DE3) containing pET32a(+)-PTH84 from the LB agar 
pellet and cultivated six randomly selected colonies in LB broth. The expression 
levels of the six colonies were quantiﬁed by densitometry. We decided a strain 
whose expression ability was relatively strongest among the colonies as the 
fermentation seed(Wang, 2010). For achieving high cell density in manual fed 
batch, we try to following (specific growth rate) constant µ strategy for feeding. 
For this reason, increasing the feeding must be exponentially as was shown in 
Fig3. 
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Before feeding 1, for better agitation and respiration of E.coli increased rate of 
impeller and flow of air. Reduction of pH showed growth of E.coli, feeding 1 
consist of glucose is Source of carbon. As OD was measured continuously, we 
saw that it’s constant and maybe decreases (end of the growth phase).at this 
point, we achieved high cell density and it was a good time for inducing with 
feeding 2, containing lactose, and IPTG. We saw that after induction with 
lactose, the T7 promoter led a highly effective expression of fusion protein. 
  
 Essentially, induction of PTH expression was started when the OD595 of the 
cultures achieved 100, after which the cultivated mediums were sampled at 4 h 
intervals to detect the expression level by glycine SDS–PAGE. (Fig 4) 
 With 18 h cultivation, about 81 g/l cell (wet weight) was achieved. Fusion 
protein was in a soluble form and could reach 30% of the total protein. The 
harvested cells (680 g in 8 L) were suspended in 3 L buffer DTT and 
homogenized. There were about 13.5 g/l total soluble proteins in the 
supernatant after centrifugation measured by method of Bradford.   
This new production method is potentially a useful strategy for the large scale 
preparation of bioactive peptides due to its high yield, low cost and easy 
handling(Fang et al., 2009). 
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